临床试验
疾病
医学
药物试验
阿尔茨海默病
认知
食品药品监督管理局
神经科学
病理
精神科
心理学
药理学
作者
Shreya Asher,Ronny Priefer
出处
期刊:Life Sciences
[Elsevier]
日期:2022-10-01
卷期号:306: 120861-120861
被引量:61
标识
DOI:10.1016/j.lfs.2022.120861
摘要
Alzheimer's disease is a progressive neurodegenerative disease typically presenting with symptoms of memory loss and cognitive decline. Existing theories for the causation of this focuses on amyloid beta plaques and neurofibrillary tau tangles. Most US Food and Drug Administration approved therapies for Alzheimer's disease target cognitive function. A multitude of clinical trials, with a variety of different targets have been conducted over the decades which have focused on the two clinical signs, with the only success being the controversial 2021 approval of an IgG1 anti-Ab antibody targeting the clearance of the Aβ plaques. Presented is a review of all previously failed Alzheimer's disease clinical trials and the rationale for their failures.
科研通智能强力驱动
Strongly Powered by AbleSci AI